Intensity Therapeutics, Inc. Common stock Cash Flow Conversion Efficiency
Intensity Therapeutics, Inc. Common stock cash flow conversion efficiency. Based on the latest financial reports, Intensity Therapeutics, Inc. Common stock (INTS) has a cash flow conversion efficiency ratio of -0.183x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.83 Million) by net assets ($9.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Intensity Therapeutics, Inc. Common stock (2019–2025)
Cash flow conversion efficiency of Intensity Therapeutics, Inc. Common stock from 2019 to 2025. This chart illustrates how Intensity Therapeutics, Inc. Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View INTS stock price for real-time trading data and today's change.
Intensity Therapeutics, Inc. Common stock Cash Flow Conversion Ratio Explained
Intensity Therapeutics, Inc. Common stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Intensity Therapeutics, Inc. Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intensity Therapeutics, Inc. Common stock ranked by their cash flow conversion efficiency. Also see INTS market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Royal Hali Iplik Tekstil Mobilya Sanayi ve Ticaret AS
IS:ROYAL
|
-1.588x |
|
GENOMTEC S.A. ZY -10
F:4VI
|
N/A |
|
Plascar Participações Industriais S.A
SA:PLAS3
|
-0.023x |
|
U-BX Technology Ltd.
NASDAQ:UBXG
|
-0.017x |
|
Presurance Holdings, Inc.
NASDAQ:PRHI
|
-0.027x |
|
Platina Resources Ltd
AU:PGM
|
-0.008x |
|
Peppermint Innovation Ltd
AU:PIL
|
0.030x |
|
Real Heart
ST:HEART
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Intensity Therapeutics, Inc. Common stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Intensity Therapeutics, Inc. Common stock from 2019 to 2025. Review Intensity Therapeutics, Inc. Common stoc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $11.88 Million | $-9.23 Million | -0.777x | +85.09% |
| 2024-12-31 | $2.92 Million | $-15.22 Million | -5.216x | -852.83% |
| 2023-12-31 | $13.16 Million | $-7.21 Million | -0.547x | -250.89% |
| 2022-12-31 | $-15.10 Million | $-5.48 Million | 0.363x | -53.85% |
| 2021-12-31 | $-8.68 Million | $-6.83 Million | 0.786x | -77.19% |
| 2020-12-31 | $-1.56 Million | $-5.37 Million | 3.446x | +700.77% |
| 2019-12-31 | $7.70 Million | $-4.42 Million | -0.574x | -- |
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is… Read more